HealthCancer Treatment
ImmunityBio's Anktiva: Asian Expansion and NCCN Guideline Inclusion
ImmunityBio's Anktiva (nogapendekin alfa inbakicept-pmln) is making significant strides in bladder cancer treatment. Recently, it secured ap...
3 months ago
HealthCancer Treatment
ImmunityBio Advances NMIBC Program with Positive ANKTIVA® Data
5 months agoUS
ImmunityBio (IBRX) is making significant strides in the treatment of non-muscle-invasive bladder cancer (NMIBC). Recent data highlights the effectiveness of ANKTIVA® when combined with Bacillus Calmette-Guérin (BCG) in BCG-naive patients. Encouraging results have led to an upgrade in the stock's rating, reflecting confidence in its potential.
Key Insights
•
Enrollment in the QUILT-2.005 trial, evaluating ANKTIVA® plus BCG in BCG-naive NMIBC patients, has exceeded expectations, reaching over 85% completion.
•
Interim analysis requested by the FDA demonstrated a statistically significant longer duration of complete response with ANKTIVA® plus BCG compared to BCG alone (p=0.0455).
•
At six months, 85% of patients receiving ANKTIVA® plus BCG maintained a complete response, compared to 57% of patients receiving BCG alone.
•
Anktiva shows superior duration of response versus competitors and promising survival data in NSCLC, supporting long-term revenue potential.
Why this matters: These results suggest ANKTIVA® could become a crucial component in first-line treatment for NMIBC, especially given the ongoing shortages of TICE BCG. The expanded access program aims to support patient access during this critical time.
In-Depth Analysis
ImmunityBio's QUILT-2.005 trial is a randomized registrational study in BCG-naive NMIBC. The interim analysis showed that ANKTIVA® significantly prolonged the duration of complete response when combined with BCG compared to BCG alone. This is particularly important because delaying cystectomy (bladder removal) can lead to more aggressive forms of bladder cancer.
The company anticipates submitting a Biologics License Application (BLA) to the FDA by the end of 2026. Moreover, ImmunityBio is in consultation with the FDA regarding the use of recombinant BCG as an alternative supply source.
Edmund Ingham from Seeking Alpha upgraded ImmunityBio to a 'Buy' rating, citing improving Anktiva data and potential label expansions in NMIBC and non-small cell lung cancer (NSCLC). The upgrade reflects growing confidence in ImmunityBio's pipeline and potential revenue streams, despite acknowledging competitive threats and ongoing cash burn as risks.
FAQs
•
Q: What is ANKTIVA®?
ANKTIVA® (nogapendekin alfa inbakicept) is an interleukin-15 (IL-15) receptor agonist used with Bacillus Calmette-Guérin (BCG) for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
•
Q: What is BCG-naive NMIBC?
BCG-naive NMIBC refers to non-muscle-invasive bladder cancer in patients who have not previously been treated with Bacillus Calmette-Guérin (BCG) therapy.
•
Q: What are the risks associated with ANKTIVA®?
Delaying cystectomy in patients who do not respond to ANKTIVA® with BCG can lead to metastatic bladder cancer.
Key Takeaways
•
ANKTIVA® shows promise as a first-line treatment for BCG-naive NMIBC, potentially offering a more effective and durable response.
•
ImmunityBio is actively working to address BCG supply shortages by consulting with the FDA on recombinant BCG as an alternative.
•
While competitive threats and financial risks exist, the positive clinical data and potential label expansions make IBRX an attractive investment.
Discussion
Do you think ANKTIVA® will become a standard treatment for NMIBC? Let us know in the comments!
Share this article with others who need to stay ahead of this trend!
Related Articles
⚠ Disclaimer: Yanuki provides article summaries and links for reference only. Yanuki does not endorse, verify, or guarantee the accuracy of third-party sources. Please review original sources and verify information independently. Managed by the Yanuki Data Engine. Full Disclaimer